These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Aug 6, 2020Commercialization and launch of first royalty bearing products position company for next phase of growth
SAN DIEGO, August 6, 2020 — Pfenex Inc. (NYSE American: PFNX) reported financial results for the second quarter ended June 30, 2020 and provided a business update. “The second quarter of 2020...
-
Jul 20, 2020
SAN DIEGO, July 20, 2020 — Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended June 30, 2020, after the market close on...
-
Jun 26, 2020
Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Livogiva marks important first step toward marketing authorization Pfenex’s commercial partner Adalvo entered into...
-
Jun 12, 2020Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United States
SAN DIEGO, June 12, 2020 —Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States. Teriparatide...
-
Jun 5, 2020
SAN DIEGO, June 5, 2020 —Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat at the William...
-
May 7, 2020
SAN DIEGO, May 7, 2020 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform, Pfenex...
-
Apr 24, 2020
SAN DIEGO, April 24, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the market close on...
-
Apr 14, 2020FDA review for a Therapeutic Equivalency rating for PF708 continues
SAN DIEGO, April 14, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA), informed Alvogen Malta Operations Ltd., the Company’s...
-
Mar 11, 2020Alvogen is preparing for commercial launch of PF708 upon receiving FDA decision on therapeutic equivalence to Forteo® | Jazz initiated a pivotal Phase 2/3 Study for FDA fast track designated PF743 (JZP-458) for the treatment of ALL/LBL | Earned $31.1 million in development and regulatory milestone payments in FY 2019
SAN DIEGO, March 11, 2020 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Feb 27, 2020
SAN DIEGO, February 26, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019, after the...
-
Jan 8, 2020
SAN DIEGO, January 8, 2020 - Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO)...
-
Dec 18, 2019
SAN DIEGO, December 18, 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz...
-
Nov 20, 2019
SAN DIEGO, November 20, 2019 —Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Nov 19, 2019
SAN DIEGO, November 19, 2019 —Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Nov 13, 2019
SAN DIEGO, November 13, 2019 — Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial...
-
Nov 7, 2019Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence rating relative to Forteo® | Announced partnership with Arcellx to develop SparX proteins used in cell therapies | Jazz advances PF743 (JZP-458) to pivotal Phase 2/3 Study expected to be initiated later this year; Jazz also announced FDA fast track designation for JZP-458, for the treatment of ALL/LBL | Earned $13.5 million in development and regulatory milestone payments
SAN DIEGO, November 7, 2019 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Nov 6, 2019
Conference: Jefferies 2019 London Healthcare Conference Date: Wednesday, November 20, 2019 Time: 4:00 p.m. GMT (8:00 a.m. PST) Webcast: Interested parties can access the live audio webcast and...
-
Oct 24, 2019
SAN DIEGO, October 24, 2019-- Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve...
-
Oct 14, 2019Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks | Pfenex believes the study report completes the information package required by the FDA to evaluate the FDA-approved PF708 product for therapeutic equivalence
SAN DIEGO, October 14, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today it has successfully completed the PF708 comparative use human factors (HF) study and submitted the final study...
-
Oct 11, 2019New Exclusive Commercialization Agreements in South Korea, Canada, and Israel | Submission of Marketing Authorization Application for PF708 in Saudi Arabia | Potential approval of PF708 in the EU as early as the second half of 2020
SAN DIEGO, October [11], 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that its partner Alvogen has entered into exclusive commercialization agreements for PF708 with PharmBio Korea...
-
Oct 7, 2019Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval. Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019
SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for PF708...
-
Sep 16, 2019
SAN DIEGO, September 16, 2019—Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Sep 10, 2019
SAN DIEGO, September 10, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Sep 5, 2019
SAN DIEGO, September 5, 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement with Jazz...
-
Sep 4, 2019
SAN DIEGO, September 5th, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...